减剂量阿哌沙班延长治疗活动性癌症相关静脉血栓栓塞症
该随机、双盲、非劣效试验纳入活动性癌症及近端深静脉血栓或肺栓塞、已完成至少6个月抗凝治疗的患者,1:1随机接受口服阿哌沙班减剂量2.5 mg或全剂量5.0 mg每日两次,共12个月。主要终点复发VTE在减剂量组18例(累积发生率2.1%)、全剂量组24例(2.8%),校正亚风险比0.76(95%CI 0.41-1.41),非劣效P=0.001。关键次要终点临床相关出血减剂量组102例(12.1%)低于全剂量组136例(15.6%),校正亚风险比0.75(95%CI 0.58-0.97),优效性P=0.03。两组死亡率分别为17.7%与19.6%,校正风险比0.96(95%CI 0.86-1.06)。
要点
- 活动性癌症相关VTE完成≥6个月抗凝后,减剂量阿哌沙班2.5 mg每日两次延长治疗12个月,复发VTE非劣效于全剂量5.0 mg(校正亚风险比0.76,95%CI 0.41-1.41,非劣效P=0.001)。
- 减剂量组临床相关出血累积发生率12.1%(102例),低于全剂量组15.6%(136例),校正亚风险比0.75(95%CI 0.58-0.97,P=0.03)。
- 两组死亡率分别为17.7%与19.6%,校正风险比0.96(95%CI 0.86-1.06),未见差异。
- 入组时距索引事件中位8.0个月(四分位距6.5-12.6),中位治疗时长11.8个月(四分位距8.3-12.1)。
适用人群与场景
- 活动性癌症合并近端深静脉血栓或肺栓塞、已完成至少6个月抗凝治疗的患者;连续入组。
诊断标准与关键阈值
- 非劣效界值:主要终点亚风险比95%CI上限为2.00。
处置流程与药物剂量
- 口服阿哌沙班减剂量2.5 mg每日两次,或全剂量5.0 mg每日两次,疗程12个月。
研究设计与关键结果
- 随机、双盲、非劣效试验,盲法中心化结局裁定,共1766例随机:减剂量组866例,全剂量组900例。
- 主要终点复发VTE:减剂量组18例(累积发生率2.1%)vs 全剂量组24例(累积发生率2.8%),校正亚风险比0.76(95%CI 0.41-1.41),非劣效P=0.001。
- 关键次要终点临床相关出血:减剂量组102例(累积发生率12.1%)vs 全剂量组136例(累积发生率15.6%),校正亚风险比0.75(95%CI 0.58-0.97),优效性P=0.03。
- 死亡:减剂量组17.7% vs 全剂量组19.6%,校正风险比0.96(95%CI 0.86-1.06)。
证据类型、等级与局限
- 随机、双盲、非劣效试验,盲法中心化结局裁定;由Bristol-Myers Squibb-Pfizer Alliance资助;API-CAT试验,ClinicalTrials.gov注册号NCT03692065。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对活动性癌症相关VTE已完成至少6个月抗凝的患者,延长抗凝时可考虑减剂量阿哌沙班2.5 mg每日两次替代全剂量5.0 mg每日两次,以在维持VTE预防效果的同时减少临床相关出血。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and decreasing bleeding is unclear.
METHODS: We conducted a randomized, double-blind, noninferiority trial with blinded central outcome adjudication. Consecutive patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism who had completed at least 6 months of anticoagulant therapy were randomly assigned in a 1:1 ratio to receive oral apixaban at a reduced (2.5 mg) or full (5.0 mg) dose twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal recurrent venous thromboembolism, assessed in a noninferiority analysis (margin of 2.00 for the upper boundary of the 95% confidence interval of the subhazard ratio). The key secondary outcome was clinically relevant bleeding, assessed in a superiority analysis.
RESULTS: A total of 1766 patients underwent randomization at a median time since the index event of 8.0 months (interquartile range, 6.5 to 12.6); 866 patients were assigned to the reduced-dose group, and 900 to the full-dose group. The median treatment duration was 11.8 months (interquartile range, 8.3 to 12.1). Recurrent venous thromboembolism occurred in 18 patients (cumulative incidence, 2.1%) in the reduced-dose group and in 24 (cumulative incidence, 2.8%) in the full-dose group (adjusted subhazard ratio, 0.76; 95% confidence interval [CI], 0.41 to 1.41; P = 0.001 for noninferiority). Clinically relevant bleeding occurred in 102 patients (cumulative incidence, 12.1%) in the reduced-dose group and in 136 (cumulative incidence, 15.6%) in the full-dose group (adjusted subhazard ratio, 0.75; 95% CI, 0.58 to 0.97; P = 0.03). Mortality was 17.7% in the reduced-dose group and 19.6% in the full-dose group (adjusted hazard ratio, 0.96; 95% CI, 0.86 to 1.06).
CONCLUSIONS: Extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for the prevention of recurrent venous thromboembolism in patients with active cancer. The reduced dose led to a lower incidence of clinically relevant bleeding complications than the full dose. (Funded by the Bristol-Myers Squibb-Pfizer Alliance; API-CAT ClinicalTrials.gov number, NCT03692065.).
参考来源
- Mahé I, Carrier M, Mayeur D, et al. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2025. PMID: 40162636. doi:10.1056/NEJMoa2416112
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。